Next 10 |
2024-05-08 08:30:00 ET Growth stocks have resoundingly outperformed value and dividend stocks since the 2008 financial crisis. While this trend is a reversal relative to historical norms, growth stocks are likely to continue to deliver outstanding returns over the long term due to the emerg...
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2024 Healthcare Confere...
2024-05-07 12:55:52 ET Summary Kura Oncology's stock is likely to maintain a holding pattern in the near term due to lack of major clinical catalysts in 2024. The company's pipeline candidate, ziftomenib, has shown promising results in AML, but there is potential competition in th...
2024-05-04 17:28:08 ET Kura Oncology, Inc. (KURA) Q1 2024 Earnings Conference Call May 2, 2024 04:30 PM ET Company Participants Pete De Spain - EVP, IR Troy Wilson - President & CEO Thomas Doyle - SVP of Finance & Accounting Conference Call Particip...
2024-05-02 17:18:06 ET Gainers: AXT ( AXTI ) +20% . El Pollo Loco Holdings ( LOCO ) +14% . Tandem Diabetes Care ( TNDM ) +12% . Ardelyx ( ARDX ) +12% . Opendoor Technologies ( OPEN ) +11% . Losers: Kura Oncolo...
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data for ziftomenib in NPM1-mutant an...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
2024-05-01 17:20:28 ET More on Kura Oncology Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation Cantor sees strong year ahead for oncology M&A Kura Oncology GAAP EPS of -$0.55 in-...
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the cl...
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOB...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing...
2024-05-08 08:30:00 ET Growth stocks have resoundingly outperformed value and dividend stocks since the 2008 financial crisis. While this trend is a reversal relative to historical norms, growth stocks are likely to continue to deliver outstanding returns over the long term due to the emerg...
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2024 Healthcare Confere...